Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 04:40:19 2024-04-23 am EDT			5-day change	1st Jan Change
147.9 ^EUR	+0.14%		-1.89%	+2.88%

Apr. 19	MERCK KGAA : Barclays reiterates its Buy rating	ZD
Apr. 18	Study: US companies outpace Europe and Asia in research spending	DP

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year of 2022

May 12, 2022 at 08:00 am EDT

MERCK Kommanditgesellschaft auf Aktien provided earnings guidance for the full year of 2022. The company is anticipating net sales in a range of EUR 21.6 billion to EUR 22.8 billion and EBITDA pre of EUR 6.6 billion to EUR 7.1 billion with EPS pre of EUR 9.60 billion to EUR 10.50 billion.

Latest news about Merck KGaA

MERCK KGAA : Barclays reiterates its Buy rating	Apr. 19	ZD
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Agronomics Portfolio Company Mosa Meat Raises EUR40 Million to Beef Up Production	Apr. 17	MT
Merck KGaA Rolls Out New Genetic Stability Assay Platform	Apr. 16	MT
MERCK : A peer group tidy up	Apr. 13
Merck Announces Change of Managing Director of Merck Life Science in India	Apr. 09	CI
Caris Life Sciences Announces Partnership with Merck KGaA to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development	Apr. 04	CI
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	CI
UBS Raises Merck KGaA PT, Keeps Buy Rating	Mar. 26	MT
MERCK KGAA : Jefferies keeps its Buy rating	Mar. 26	ZD
MERCK KGAA : price target raised by UBS	Mar. 26	CF
MERCK KGAA : Buy rating from UBS	Mar. 26	ZD
Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia	Mar. 20	DJ
Merck KGaA Spends EUR300 Million on New Bioprocessing Site in South Korea	Mar. 20	MT
MERCK KGAA : DZ Bank gives a Buy rating	Mar. 20	ZD
MERCK KGAA : JP Morgan gives a Buy rating	Mar. 18	ZD
MERCK KGAA : Barclays gives a Buy rating	Mar. 12	ZD
Deutsche Bank raises target for Merck KGaA to 175 euros - 'Buy'	Mar. 12	DP
MERCK KGAA : Deutsche Bank remains its Buy rating	Mar. 12	ZD
MERCK : A weak finish but the 2024 guidance leaves room for positives	Mar. 08
MERCK KGAA : Deutsche Bank reiterates its Buy rating	Mar. 08	ZD
German Equities Rise as ECB Opens Up to Rate Cuts	Mar. 07	MT
Global markets live: Darktrace, Merck, Meta, Apple, Eli Lilly...	Mar. 07
MERCK KGAA : Jefferies remains its Buy rating	Mar. 07	ZD
Merck KGaA Provides Earnings Guidance for the Year 2024	Mar. 07	CI

Chart Merck KGaA

Duration

Period

More charts

Company Profile

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

MERCK : A peer group tidy up

April 13, 2024 at 04:06 pm EDT

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am EST

More Strategies

Ratings for Merck KGaA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

147.7 EUR

Average target price

182 EUR

Spread / Average Target

+23.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+2.88%	68.35B
SK BIOPHARMACEUTICALS CO., LTD.	-16.14%	4.78B
YUHAN CORPORATION	+4.07%	3.87B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+19.02%	3.73B
INDIVIOR PLC	+26.33%	2.52B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-27.48%	2.27B
BETTA PHARMACEUTICALS CO., LTD.	-25.70%	2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.46%	1.95B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	+2.66%	1.63B

Specialty & Advanced Pharmaceuticals

Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year of 2022

EPS Revisions